JP7849854B2 - シヌクレイノパチーを予防又は治療するために使用されるペプチド - Google Patents

シヌクレイノパチーを予防又は治療するために使用されるペプチド

Info

Publication number
JP7849854B2
JP7849854B2 JP2021112822A JP2021112822A JP7849854B2 JP 7849854 B2 JP7849854 B2 JP 7849854B2 JP 2021112822 A JP2021112822 A JP 2021112822A JP 2021112822 A JP2021112822 A JP 2021112822A JP 7849854 B2 JP7849854 B2 JP 7849854B2
Authority
JP
Japan
Prior art keywords
synuclein
peptide
fabp3
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021112822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022027513A5 (https=
JP2022027513A (ja
Inventor
浩司 福永
伊知郎 川畑
康志 河田
知宏 溝端
直也 福井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Original Assignee
Tohoku University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC filed Critical Tohoku University NUC
Publication of JP2022027513A publication Critical patent/JP2022027513A/ja
Publication of JP2022027513A5 publication Critical patent/JP2022027513A5/ja
Application granted granted Critical
Publication of JP7849854B2 publication Critical patent/JP7849854B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021112822A 2020-07-29 2021-07-07 シヌクレイノパチーを予防又は治療するために使用されるペプチド Active JP7849854B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020127958 2020-07-29
JP2020127958 2020-07-29

Publications (3)

Publication Number Publication Date
JP2022027513A JP2022027513A (ja) 2022-02-10
JP2022027513A5 JP2022027513A5 (https=) 2024-07-30
JP7849854B2 true JP7849854B2 (ja) 2026-04-22

Family

ID=80036234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021112822A Active JP7849854B2 (ja) 2020-07-29 2021-07-07 シヌクレイノパチーを予防又は治療するために使用されるペプチド

Country Status (5)

Country Link
US (1) US20230242601A1 (https=)
EP (1) EP4190797A4 (https=)
JP (1) JP7849854B2 (https=)
CN (1) CN115667281A (https=)
WO (1) WO2022024693A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025192147A1 (ja) * 2024-03-15 2025-09-18 公益財団法人東京都医学総合研究所 αシヌクレインの蓄積抑制用の組成物、及びその利用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517389A (ja) 2001-11-20 2005-06-16 アトゲン カンパニー リミティッド 環境ストレス耐性を有する新規のペプチド及びこれを含む融合蛋白質
JP2008509223A (ja) 2004-08-09 2008-03-27 エラン ファーマシューティカルズ，インコーポレイテッド シヌクレイノパシー（ｓｙｎｕｃｌｅｉｎｏｐａｔｈｉｃ）およびアミロイド生成性疾患の予防および処置
US20180134775A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (7A11)
US20200095296A1 (en) 2017-06-05 2020-03-26 The Trustees Of Columbia University In The City Of New York Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder and tcr and/or hla immunoprofiling in neurodegenerative disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
WO2005108423A1 (en) * 2004-05-11 2005-11-17 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
CN101052417A (zh) * 2004-08-09 2007-10-10 艾兰制药公司 突触核蛋白病以及淀粉样变性病的预防和治疗
PL2118300T3 (pl) * 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
AT508638B1 (de) * 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
GB201008682D0 (en) * 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
CA2924268C (en) 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
CN110506057B (zh) * 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
WO2020181273A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517389A (ja) 2001-11-20 2005-06-16 アトゲン カンパニー リミティッド 環境ストレス耐性を有する新規のペプチド及びこれを含む融合蛋白質
JP2008509223A (ja) 2004-08-09 2008-03-27 エラン ファーマシューティカルズ，インコーポレイテッド シヌクレイノパシー（ｓｙｎｕｃｌｅｉｎｏｐａｔｈｉｃ）およびアミロイド生成性疾患の予防および処置
US20180134775A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (7A11)
US20200095296A1 (en) 2017-06-05 2020-03-26 The Trustees Of Columbia University In The City Of New York Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder and tcr and/or hla immunoprofiling in neurodegenerative disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ichiro KAWAHATA et al.，Fatty Acid-Binding Protein 3 is Critical for α-Synuclein Uptake and MPP+-Induced Mitochondrial Dysfunction in Cultured Dopaminergic Neurons，International Journal of Molecular Sciences，2019年10月28日，Vol. 20，No. 21，5358，DOI:10.3390/ijms20215358
Jaime I. AREVALO-VILLALOBOS et al.，LTB-Syn: a recombinant immunogen for the development of plant-made vaccines against synucleinopathies，Planta，Vol. 245，No. 6，2017年03月17日，p.1231-1239，DOI:10.1007/s00425-017-2675-y
Joanna KAYLOR et al.，Characterization of Oligomeric Intermediates in α-Synuclein Fibrillation: FRET Studies of Y125W/Y133F/Y136F α-Synuclein，Journal of Molecular Biology，Vol. 353，No. 2，2005年10月，p.357-372，DOI: 10.1016/j.jmb.2005.08.046
Joanna KAYLOR et al.，Characterization of Oligomeric Intermediates in α-Synuclein Fibrillation:FRET Studies of Y125W/Y133F/Y136F α-Synuclein，Journal of Molecular Biology，Vol. 353，No. 2，2005年10月，p.357-372，DOI: 10.1016/j.jmb.2005.08.046
Robert W. NEWBERRY et al.，Deep mutational scanning reveals the structural basis for α-synuclein activity，Nature Chemical Biology，2020年03月09日，Vol. 16, No. 6，p.653-659，DOI: 10.1038/s41589-020-0480-6

Also Published As

Publication number Publication date
EP4190797A4 (en) 2024-09-04
CN115667281A (zh) 2023-01-31
WO2022024693A1 (ja) 2022-02-03
JP2022027513A (ja) 2022-02-10
US20230242601A1 (en) 2023-08-03
EP4190797A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
US6780971B2 (en) Compositions for inhibiting the aggregation pathway of α-synuclein
CN104147591B (zh) Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗各种疾病的应用
JP7204235B2 (ja) 活性型α－シヌクレインに結合する抗体
CZ20011608A3 (cs) Nukleotidové a proteinové sekvence genů Nogo a metody na nich zaloľené
US8021658B2 (en) Alternative splice forms of proteins as basis for multiple therapeutic modalities
JP2010046088A (ja) 新規なぺプチド類
WO2011113048A2 (en) Modulation of cytokine signaling
US20150297693A1 (en) Peptide inhibitors for mediating stress responses
JP7849854B2 (ja) シヌクレイノパチーを予防又は治療するために使用されるペプチド
AU2013326552B2 (en) Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein
JP2008540339A (ja) Ｎｏｇｏレセプター機能モチーフおよびそれに関するペプチド模倣物、ならびにそれらを使用する方法
AU2005221187B2 (en) Method for inhibiting immune complex formation in a subjetc
KR20220155367A (ko) MS 치료를 위한 카파 오피오이드 수용체(kappa opioid receptor) 리간드와 조합된 사이클로타이드(cyclotide)
CN117279887A (zh) 抑制剂及其用途
US20250352614A1 (en) Peptide therapeutics for the treatment of cancer and uses thereof
AU2011253771B2 (en) Method for inhibiting immune complex formation in a subject
EP1301534B1 (fr) PF-4 MUTE, SES FRAGMENTS ET PEPTIDES DE FUSION MUTES, LEURS ANALOGUES, LES SEQUENCES D'ADN, ADNc ET ARNm CORRESPONDANTES, ET LEUR UTILISATION DANS L'INHIBITION DE L'ANGIOGENESE
WO2021242757A1 (en) Monocolonal antibodies against pathological tau, and methods using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260403